|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China显示文摘Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains unclear.Methods A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients’ medical records. Multivariable logistic regression models were used to estimate the odds ratio(OR) and 95% confidence interval(95% CI) of the associations between comorbidities(cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of COVID-19.Results Overall, 158(13.6%) patients were diagnosed with severe illness and 32(2.7%) had unfavorable outcomes. Hypertension(2.87, 1.30–6.32), type 2 diabetes(T2 DM)(3.57, 2.32–5.49),cardiovascular disease(CVD)(3.78, 1.81–7.89), fatty liver disease(7.53, 1.96–28.96), hyperlipidemia(2.15, 1.26–3.67), other lung diseases(6.00, 3.01–11.96), and electrolyte imbalance(10.40, 3.00–26.10)were independently linked to increased odds of being severely ill. T2 DM(6.07, 2.89–12.75), CVD(8.47,6.03–11.89), and electrolyte imbalance(19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission(5.46,3.25–9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes(6.58, 1.46–29.64) within two weeks.Conclusion Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes. | MA Yan ZHU Dong Shan CHEN Ren Bo SHI Nan Nan LIU Si Hong FAN Yi Pin WU Gui Hui YANG Pu Ye BAI Jiang Feng CHEN Hong CHEN Li Ying FENG Qiao GUO Tuan Mao HOU Yong HU Gui Fen HU Xiao Mei HU Yun Hong HUANG Jin HUANG Qiu Hua HUANG Shao Zhen JI Liang JIN Hai Hao LEI Xiao LI Chun Yan LI Min Qing LI Qun Tang LI Xian Yong LIU Hong De LIU Jin Ping LIU Zhang MA Yu Ting MAO Ya MO Liu Fen NA Hui WANG Jing Wei SONG Fang Li SUN Sheng WANG Dong Ting WANG Ming Xuan WANG Xiao Yan WANG Yin Zhen WANG Yu Dong WU Wei WU Lan Ping XIAO Yan Hua XIE Hai Jun XU Hong Ming XU Shou Fang XUE Rui Xia YANG Chun YANG Kai Jun YUAN Sheng Li ZHANG Gong Qi ZHANG Jin Bo ZHANG Lin Song ZHAO Shu Sen ZHAO Wan Ying ZHENG Kai ZHOU Ying Chun ZHU Jun Teng ZHU Tian Qing ZHANG Hua Min WANG Yan Ping WANG Yong Yan 无 | 2020 | Biomedical and Environmental Sciences2020，33，12： | 8 |
| 2 | The landscape of aging显示文摘Aging is characterized by a progressive deterioration of physiological integrity,leading to impaired functional ability and ultimately increased susceptibility to death.It is a major risk factor for chronic human diseases,including cardiovascular disease,diabetes,neurological degeneration,and cancer.Therefore,the growing emphasis on “healthy aging” raises a series of important questions in life and social sciences.In recent years,there has been unprecedented progress in aging research,particularly the discovery that the rate of aging is at least partly controlled by evolutionarily conserved genetic pathways and biological processes.In an attempt to bring full-fledged understanding to both the aging process and age-associated diseases,we review the descriptive,conceptual,and interventive aspects of the landscape of aging composed of a number of layers at the cellular,tissue,organ,organ system,and organismal levels. | Yusheng Cai Wei Song Jiaming Li Ying Jing Chuqian Liang Liyuan Zhang Xia Zhang Wenhui Zhang Beibei Liu Yongpan An Jingyi Li Baixue Tang Siyu Pei Xueying Wu Yuxuan Liu Cheng-Le Zhuang Yilin Ying Xuefeng Dou Yu Chen Fu-Hui Xiao Dingfeng Li Ruici Yang Ya Zhao Yang Wang Lihui Wang Yujing Li Shuai Ma Si Wang Xiaoyuan Song Jie Ren Liang Zhang Jun Wang Weiqi Zhang Zhengwei Xie Jing Qu Jianwei Wang Yichuan Xiao Ye Tian Gelin Wang Ping Hu Jing Ye Yu Sun Zhiyong Mao Qing-Peng Kong Qiang Liu Weiguo Zou Xiao-Li Tian Zhi-Xiong Xiao Yong Liu Jun-Ping Liu Moshi Song Jing-Dong J.Han Guang-Hui Liu | 2022 | Science China(Life Sciences)2022，65，12： | 4 |
| 3 | Bio-inspired design of hierarchical FeP nanostructure arrays for the hydrogen evolution reaction显示文摘由 FeP nanopetals 组成的层次 FeP nanoarray 电影成功地经由 phosphorization 跟随的一条启发简历的热水的线路被综合。作为一个水晶生长修饰词,甘油在控制 FeO 的形态学和结构起一个重要作用(哦) 先锋在 biomineralization 过程期间,当时 FeO 的下列转移和 pseudomorphic 转变(哦) 电影成功地产生 FeP 数组电影。同样准备的 FeP 电影电极展出优秀的氢进化反应(她的) 在一个宽 pH 范围上的性能。理论计算表明在 FeP 电影的混合 P/Fe 结束为 nanostructured 电极的高催化的活动负责。这新卓见将支持有效金属的进一步的探索为 HER 的基于 phosphoride 的催化剂。更重要地,这研究衔接在生物、无机的自我装配的 nanosystems 之间的差距并且可以在精力设备用申请为功能的 nanostructures 的准备开创一条新大街。 | Ya Yan Xue Rong Shi Mao Miao Ting He Ze Hua Dong Ke Zhan Jun He Yang Bin Zhao Bao Yu Xia | 2018 | Nano Research2018，11，7： | 2 |
| 4 | Panda X-III: Searching for neutrinoless double beta decay with high pressure ^(136)Xe gas time projection chambers显示文摘Searching for the neutrinoless double beta decay(NLDBD)is now regarded as the topmost promising technique to explore the nature of neutrinos after the discovery of neutrino masses in oscillation experiments.Panda X-III(particle and astrophysical xenon experiment III)will search for the NLDBD of136Xe at the China Jin Ping Underground Laboratory(CJPL).In the first phase of the experiment,a high pressure gas Time Projection Chamber(TPC)will contain 200 kg,90%136Xe enriched gas operated at10 bar.Fine pitch micro-pattern gas detector(Microbulk Micromegas)will be used at both ends of the TPC for the charge readout with a cathode in the middle.Charge signals can be used to reconstruct the electron tracks of the NLDBD events and provide good energy and spatial resolution.The detector will be immersed in a large water tank to ensure~5 m of water shielding in all directions.The second phase,a ton-scale experiment,will consist of five TPCs in the same water tank,with improved energy resolution and better control over backgrounds. | Xun Chen Chang Bo Fu Javier Galan Karl Giboni Franco Giuliani Ling Hui Gu Ke Han Xiang Dong Ji Heng Lin Jiang Lai Liu Kai Xiang Ni Hiroki Kusano Xiang Xiang Ren Shao Bo Wang Yong Yang Dan Zhang Tao Zhang Li Zhao Xiang Ming Sun Shou Yang Hu Si Yu Jian Xing Long Li Xiao Mei Li Hao Liang Huan Qiao Zhang Ming Rui Zhao Jing Zhou Ya Jun Mao Hao Qiao Si Guang Wang Ying Yuan Meng Wang Amir N.Khan Neill Raper Jian Tang Wei Wang Jia Ning Dong Chang Qing Feng Cheng Li Jian Bei Liu Shu Bin Liu Xiao Lian Wang Dan Yang Zhu Juan F.Castel Susana Cebri'an Theopisti Dafni Javier G.Garza Igor G.Irastorza Francisco J.Iguaz Gloria Luz ′on Hector Mirallas Stephan Aune Eric Berthoumieux Yann Bedfer Denis Calvet Nicole d'Hose Alain Delbart Maria Diakaki Esther Ferrer-Ribas Andrea Ferrero Fabienne Kunne Damien Neyret Thomas Papaevangelou Franck Sabatie Maxence Vanderbroucke AnDi Tan Wick Haxton Yuan Mei Chinorat Kobdaj Yu-Peng Yan | 2017 | Science China(Physics,Mechanics & Astronomy)2017，60，6： | 2 |
| 5 | Antistress Effect of TRPV1 Channel on Synaptic Plasticity and Spatial Memory显示文摘 | Hong-Bin Li Rong-Rong Mao Ji-Chuan Zhang Ya Yang Jun Cao Lin Xu | 2008 | Biological Psychiatry2008，，4： | 1 |
| 6 | Curculigoside at- tenuates human umbilical vein endothelial cell injury induced by H202 显示文摘 | Yun Kai Wang Ya Jun Hong Mao Wei | 2010 | Joumal of Ethnopharmacology2010，132，： | 1 |
| 7 | Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants:a randomized phase 2 trial显示文摘An ongoing randomized,double-blind,controlled phase 2 trial was conducted to evaluate the safety and immunogenicity of a mosaic-type recombinant vaccine candidate,named NVSI-06-09,as a booster dose in subjects aged 18 years and older from the United Arab Emirates(UAE),who had administered two or three doses of inactivated vaccine BBIBP-CorV at least 6 months prior to enrollment.The participants were randomly assigned with 1:1 to receive a booster dose of NVSI-06-09 or BBIBP-CorV.The primary outcomes were immunogenicity and safety against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)Omicron variant,and the exploratory outcome was cross-immunogenicity against other circulating strains.Between May 25 and 30,2022,516 adults received booster vaccination with 260 in NVSI-06-09 group and 256 in BBIBP-CorV group.Interim results showed a similar safety profile between two booster groups,with low incidence of adverse reactions of grade 1 or 2.For immunogenicity,by day 14 post-booster,the fold rises in neutralizing antibody geometric mean titers(GMTs)from baseline elicited by NVSI-06-09 were remarkably higher than those by BBIBP-CorV against the prototype strain(19.67 vs 4.47-fold),Omicron BA.1.1(42.35 vs 3.78-fold),BA.2(25.09 vs 2.91-fold),BA.4(22.42 vs 2.69-fold),and BA.5 variants(27.06 vs 4.73-fold).Similarly,the neutralizing GMTs boosted by NVSI-06-09 against Beta and Delta variants were also 6.60-fold and 7.17-fold higher than those by BBIBP-CorV.Our findings indicated that a booster dose of NVSI-06-09 was well-tolerated and elicited broad-spectrum neutralizing responses against divergent SARS-CoV-2 variants,including Omicron and its sub-lineages. | Nawal Al Kaabi Yun Kai Yang Yu Liang Ke Xu Xue Feng Zhang Yun Kang Yu Qin Jin Jun Wei Hou Jing Zhang Tian Yang Salah Hussein Mohamed Saif ElDein Ze Hua Lei Hao Zhang Shuai Shao Zhao Ming Liu Ning Liu Xiang Zheng Ji Guo Su Sen Sen Yang Xiangfeng Cong Yao Tan Wenwen Lei Xue Jun Gao Zhiwei Jiang Hui Wang Meng Li Hanadi Mekki Mekki Walid Zaher Sally Mahmoud Xue Zhang Chang Qu Dan Ying Liu Jing Zhang Mengjie Yang Islam Eltantawy Peng Xiao Fu Jie Shen Jin Juan Wu Zi Bo Han Li Fang Du Fang Tang Shi Chen Zhi Jing Ma Fan Zheng Ya Nan Hou Xin Yu Li Xin Li Zhao Nian Wang Jin Liang Yin Xiao Yan Mao Jin Zhang Liang Qu Yun Tao Zhang Xiao Ming Yang Guizhen Wu Qi Ming Li | 2023 | Signal Transduction and Targeted Therapy2023，8，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员